The role of Rho/ROCK in epileptic seizure-related neuronal damage.
Zhihan WangDabin RenZheng PingPublished in: Metabolic brain disease (2022)
Epilepsy is one of the most severe neurological disorders characterized by spontaneous recurrent seizures. Although more than two-thirds of patients can be cured with anti-epileptic drugs (AEDs), the rest one-third of epilepsy patients are resistant to AEDs. A series of studies have demonstrated Rho/Rho-associated kinase (ROCK) pathway might be involved in the pathogenesis of epilepsy in the recent twenty years. Several related pathway inhibitors of Rho/ROCK have been used in the treatment of epilepsy. We searched PubMed from Jan 1, 2000 to Dec 31, 2020, using the terms "epilepsy AND Rho AND ROCK" and "seizure AND Rho AND ROCK". We selected articles that characterized Rho/ROCK in animal models of epilepsy and patients. We then chose the most relevant research studies including in-vitro, in-vivo and clinical trials. The expression of Rho/ROCK could be a potential non-invasive biomarker to apply in treatment for patients with epilepsy. RhoA and ROCK show significant upregulation in the acute and chronic stage of epilepsy. ROCK inhibitors can reduce the epilepsy, epileptic seizure-related neuronal death and comorbidities. These findings demonstrate the novel development for diagnosis and treatment for patients with epilepsy. Rho/ROCK signaling pathway inhibitors may show more promising effects in epilepsy and related neurological diseases.
Keyphrases
- temporal lobe epilepsy
- end stage renal disease
- protein kinase
- ejection fraction
- clinical trial
- newly diagnosed
- signaling pathway
- chronic kidney disease
- smooth muscle
- poor prognosis
- peritoneal dialysis
- prognostic factors
- patient reported outcomes
- hepatitis b virus
- intensive care unit
- cell proliferation
- blood brain barrier
- long non coding rna